A Pilot Study: Safety and Immunological Response following Intradermal COVID-19 vaccinatio
- Conditions
- healthy volunteerSafety and Immunological ResponseIntradermalCOVID-19 vaccination
Recruitment & Eligibility
- Status
- Pending (Not yet recruiting)
- Sex
- All
- Target Recruitment
- 80
1. Males or females at least 18-60 years of age, 2. Have not received any COVID-19 vaccine?, 3. Can understand Thai language through speaking, 4. Able to communicate through electronic tools such as Google form or line, 5.Capable of attending all study visits according to the study schedule., 6. Capable of informed consent and provision of written informed consent before any study procedures
1. Have history of severe drug or vaccine allergy (anaphylaxis)?, 2. Have detected COVID-19 infection? 3. Have history of COVID-19 high risk contact?, 4. Positive result (s) from either antigen test kit, 5. Have history of Chronic respiratory disease, CVD, CKD, CVS, obesity, cancer and DM?, 6. Have received blood transfusion, plasma, blood product, blood component, immunoglobulins, antiviral or antibodies within the last 90 days?, 7. Have history of cigarettes smoking, alcohol drinking and history of drug abuse?, 8. Being pregnant?, 9. Have unstable disease or could not control the symptom?, 10. Have history of immunodeficiency or been using immunosuppressant or steroid drugs?, 11. Have any unusual symptoms or medical history that considered unable to participate in the study?
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Immunogenicity response at 2 weeks and 12 weeks after second dose IgG level
- Secondary Outcome Measures
Name Time Method Safety at 7 days after vaccination Adverse event